Singapore markets closed

Cybin Inc. (CYBN)

NYSE American - Nasdaq Real-time price. Currency in USD
Add to watchlist
0.4135-0.0165 (-3.84%)
At close: 04:00PM EDT
0.4095 -0.00 (-0.97%)
After hours: 07:56PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close0.4300
Open0.4296
Bid0.4028 x 1200
Ask0.4047 x 900
Day's range0.4010 - 0.4299
52-week range0.2100 - 0.7380
Volume5,593,476
Avg. volume5,299,424
Market cap314.133M
Beta (5Y monthly)0.93
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Business Wire

    Cybin Announces Closing of the Oversubscribed Private Placement of U.S. $150 Million

    TORONTO, March 19, 2024--Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) ("Cybin" or the "Company"), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation psychedelic-based treatment options, is pleased to announce the closing of the Company’s previously announced private placement (the "Private Placement") of 348,837,210 common shares in the capital of the Company (the "Common Shares") at a price of U.S.$0.43 pe

  • Business Wire

    Cybin to Present at Public Ventures Discovery Day on March 19th in Dallas

    TORONTO, March 18, 2024--Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) ("Cybin" or the "Company"), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation psychedelic-based treatment options, today announced participation in the upcoming Public Ventures Discovery Day on March 19, 2024 in Dallas, TX.

  • Business Wire

    Cybin Initiates Phase 2 Proof-of-Concept Study of CYB004 in Generalized Anxiety Disorder

    TORONTO, March 15, 2024--Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) ("Cybin" or the "Company"), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation psychedelic-based treatment options, today announced the initiation of a Phase 2 proof-of-concept study of CYB004, its proprietary DMT molecule in development for the treatment of GAD. In January 2024, the U.S. Food and Drug Administration ("FDA") cleared Cybin